Severity
Moderate
FDA Drug recall · Reported January 13, 2021
Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integral unit
Sca Pharmaceuticals recalled labetalol HCl 20 mg/4 mL, Injection for Intravenous Use (5mg/mL), Rx Only, 4 mL Single D… - a moderate-severity action.
labetalol HCl 20 mg/4 mL, Injection for Intravenous Use (5mg/mL), Rx Only, 4 mL Single D… was recalled by Sca Pharmaceuticals in January 13, 2021. Reason: Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integral unit. Check the official notice for the remedy. Verify recall #D-0198-2021 with the FDA Drug before acting.
The recall
Sca Pharmaceuticals issued this moderate-severity FDA Drug recall-Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integral unit.
Sourced from official FDA Drug enforcement records. Verify recall #D-0198-2021 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0198-2021) was formally reported on January 13, 2021, with the manufacturer initiating the action on December 17, 2020. It is classified under Moderate severity (Class II), with a current status of Terminated. Sca Pharmaceuticals is listed as the recalling firm, operating out of Windsor, CT. Federal records list the affected scope as 9,057 syringes.
The documented reason for this recall is: Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integral unit Distribution data in the federal record shows the product reached: Product was distributed to hospitals nationwide.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
9,057 syringes
Related Recalls
6
5 from same agency
labetalol HCl 20 mg/4 mL, Injection for Intravenous Use (5mg/mL), Rx Only, 4 mL Single Dose Syringe, SCA Pharmaceuticals, 755 Rainbow Rd., Windsor, CT, 06095, barcode 70004070028
Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integral unit
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-0198-2021 |
| Date reported | January 13, 2021 |
| Date initiated | December 17, 2020 |
| Recalling firm | Sca Pharmaceuticals |
| Firm location | Windsor, CT |
| Affected scope | 9,057 syringes |
| Distribution | Product was distributed to hospitals nationwide. |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported January 13, 2021. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.